Lapatinib-resistant HER2 (+) breast cancer cells were used in this preclinical model because the biology of these cells may represent tumors in patients who have resistant tumors after using available HER2-targeting agents, including lapatinib. This evidence concerns the gene ERBB2 and breast cancer.